MK 8150

Drug Profile

MK 8150

Alternative Names: MK-8150

Latest Information Update: 24 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 01 May 2013 Merck completes a phase I trial in Hypertension in Belgium (NCT01656408)
  • 09 Aug 2012 Merck initiates enrolment in a phase I trial for Hypertension in Belgium (NCT01656408)
  • 24 May 2012 Phase-I clinical trials in Hypertension in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top